| Description | Xemilofiban (SC 54684A) interrupts platelet aggregation, promotes thrombosis, and is used in the study of unstable angina. |
| Synonyms | SC-54684A, SC54684A, SC 54684A |
| molecular weight | 358.39 |
| Molecular formula | C18H22N4O4 |
| CAS | 149820-74-6 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| References | 1. Frederick LG,et al. Protective effect of oral xemilofiban in arterial thrombosis in dogs: increased activity in combination with aspirin. Circulation. 1998 Aug 25;98(8):813-20. 2. Mercado N, Brugts JJ, Ix JH, Shlipak MG, Dixon SR, Gersh BJ, Lemos PA, Guarneri M, Teirstein PS, Wijns W, Serruys PW, Boersma E, O'Neill WW. Usefulness of proteinuria as a prognostic marker of mortality and cardiovascular events among patients undergoing percutaneous coronary intervention (data from the Evaluation of Oral Xemilofiban in Controlling Thrombotic Events [EXCITE] trial). Am J Cardiol. 2008 Nov 1;102(9):1151-5. doi: 10.1016/j.amjcard.2008.06.035. Epub 2008 Aug 9. PubMed PMID: 18940282. 3. Sheppard LP. Xemilofiban Searle and Co. IDrugs. 1998 Jun;1(2):257-63. PubMed PMID: 18465540. 4. Gowda RM, Khan IA, Vasavada BC, Sacchi TJ. Therapeutics of platelet glycoprotein IIb/IIIa receptor antagonism. Am J Ther. 2004 Jul-Aug;11(4):302-7. Review. PubMed PMID: 15266223. |